Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database91
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis79
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System75
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt70
Adverse events in patients with cardiovascular disease taking proton pump inhibitors61
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder53
The role of artificial intelligence in pharmacovigilance for rare diseases44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database42
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System41
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database41
An updated safety review of Hidradenitis Suppurativa treatment options39
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst36
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment31
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys30
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis27
The safety of phthalate-containing medications used during pregnancy25
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects25
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study25
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism24
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS24
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile23
Long-term safety of ketamine and esketamine in treatment of depression22
Gastrointestinal and cardiovascular adverse events associated with NSAIDs22
0.077620983123779